Company: BWAY
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001171843-25-002347
Chunk: 105

Company: Brainsway Ltd.
Filing Date: 2025-04-22
Form: 20-F
Item: Item 5
Chunk 105
---
 flexible pricing models are designed to achieve market penetration  

We market our products utilizing two basic pricing
models: (i) a fixed-fee lease model enabling unlimited use; and (ii) a sales or purchase model. We also offer and/or are considering offering
a pay per use model to certain customers in certain territories. Warranty and support are either included (in varying degrees and for
varying periods) or may be purchased as part of all pricing models. Additional potential revenues may be derived from extended warranty
fees paid for the system for service coverage beyond the standard included warranty period, and from variable or usage fees based on the
number of treatments performed with the system. We are also able to leverage our platform technology, which includes the ability to treat
multiple indications using different H-coil helmets, to facilitate transactions utilizing combined pricing models often involving a single
system with one or more add-on helmets. We believe that our different pricing models offer flexibility and allow for increased market
acceptance among clinics and psychiatric professionals. Based on our commercial data, and depending on insurer reimbursement rates, we
believe our psychiatrist customers for MDD systems can generate up to approximately $10,000 of gross revenues per patient, and in some
cases more, for a course of treatment using our system. While OCD coverage is still emerging, we believe that our customers can generate
up to approximately $8,800 of gross revenues per OCD patient.

  Deep TMS has potential application to a range of psychiatric, neurological, and  

Our clinical studies, including various feasibility
studies, suggest that our Deep TMS system has the potential to serve as a platform technology that can address a potentially wide variety
of other psychiatric, neurological, and addiction disorders by using the appropriate H-Coil structure for different targeted brain regions.
We are the first and only TMS company to be cleared by the FDA for three separate mental health disorder indications based on clinically
proven efficacy as demonstrated in pivotal randomized placebo-controlled studies. Current indications include MDD, OCD, and smoking addiction.
Moreover, in August 2021, we received 510(k) clearance from the FDA expanding our MDD indication to also include treatment of depressed
patients for the reduction of comorbid anxiety symptoms (commonly referred to as anxious depression). In 2021 we also received a clearance
for a shortened three-minute depression protocol and a labeling expansion for anxious depression through subsequent 510(k) clearances.
In 2022, the FDA extended the clearance of our H7